Trials Offered by a Specific Doctor

Jason Wright, MD

Dr. Wright joined the faculty at Columbia University after completing residency and a fellowship in Gynecologic Oncology at Washington University in St. Louis. He is board certified in Obstetrics and Gynecology and Gynecologic Oncology. Dr. Wright sees women with all gynecologic cancers and has extensive training in minimally invasive surgery, robotic surgery, extended pelvic resections, and pelvic reconstructive surgery. Dr. Wright also cares for a large number of women with hereditary cancer syndromes. In addition, Dr. Wright sees women with who require complex gynecologic procedures as well as women with placenta accreta.

Dr. Wright is a nationally recognized expert in the treatment of gynecologic cancers and gynecologic surgery. He has authored over 110 articles, chapters, and textbooks. A major focus of Dr. Wright's work is the delivery of quality care to women with cancer and the improvement of outcomes of women with cancer and those who undergo surgery. Dr. Wright's primary clinical research focuses on the evaluation of novel therapeutics, targeted therapies and biologic treatments for women with gynecologic cancers. Dr. Wright is the principal investigator on a number of clinical trials and an active participant in the Gynecologic Oncology Group (GOG). Dr. Wright is a member of the Alpha Omega Alpha (AOA) Honor Society, a full member of the Society of Gynecologic Oncology, and a Fellow of the American College of Obstetricians and Gynecologists. Dr. Wright has won numerous teaching and research awards and lectures throughout the United States and internationally.

Clinical Studies Managed By Dr. Wright:
More InfoTitleSponsorIRB Number
DetailsA study for patients with ovarian cancer using biomarker HE-4 to predict recurrenceFujirebio DiagnosticsAAAN4311
Details[CLOSED] A study for patients with cancer of the ovary, fallopian tube, or primary peritoneal cancer using study drug AZD1775AstraZenecaAAAO8156
Details[CLOSED] A study for women with ovarian cancer using study drug farletuzumabMorphotekAAAP0961
DetailsCONCERTO: Study of combination tablets in women with recurrent platinum resistant epithelian ovarian cancerAstraZenecaAAAR5554
DetailsStudy of Drug in Patients with Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer who Have Received Prior ChemotherapyAstraZenecaAAAR1227
Details[CLOSED] Study of New Drug Combination in Patients with Newly-Diagnosed Ovarian, Fallopian Tube, or Primary Peritoneal CancerF. Hoffmann- La Roche Ltd.AAAR3798
Details[CLOSED] Study of Drug in Patients with Recurrent, Persistent or Metastatic Cervical CancerNCIAAAR4617
DetailsEvaluation of Fallopian Tube Cell Samples Collected by MAKO 7nVision Medical CorporationAAAR9484
DetailsStudy of CA 125 and HE4 Serum Biomarkers in Women with Ovarian, Fallopian Tube, or Primary Peritoneal Cancers (Excluding Ovarian Tumors)Fujirebio Diagnostics, Inc.AAAN4308
DetailsStudy of Pembrolizumab Plus Chemotherapy versus Chemotherapy Plus Placebo in Patients with Cervical CancerMERCK SHARP & DOHME CORPAAAS0820